COLOMBO, BENEDETTA
 Distribuzione geografica
Continente #
AS - Asia 1.062
EU - Europa 67
NA - Nord America 58
OC - Oceania 3
SA - Sud America 1
Totale 1.191
Nazione #
SG - Singapore 1.015
US - Stati Uniti d'America 53
CN - Cina 40
IT - Italia 33
FI - Finlandia 12
GB - Regno Unito 7
DE - Germania 6
CA - Canada 5
JP - Giappone 3
NL - Olanda 3
AU - Australia 2
SE - Svezia 2
BR - Brasile 1
EE - Estonia 1
FR - Francia 1
IN - India 1
IQ - Iraq 1
LT - Lituania 1
NZ - Nuova Zelanda 1
TR - Turchia 1
UA - Ucraina 1
VN - Vietnam 1
Totale 1.191
Città #
Hefei 18
Singapore 17
Ashburn 13
Boardman 9
Beijing 8
Helsinki 8
Shanghai 8
Los Angeles 6
Florence 5
Istrana 5
Munich 5
Rome 4
Seattle 4
Turku 4
Ciampino 3
London 3
Milan 3
Naples 3
San Francisco 3
Segrate 3
Bungarribee 2
Cardiff 2
Huizen 2
Lake Zurich 2
Occimiano 2
Tokyo 2
Amsterdam 1
Auckland 1
Bologna 1
Borås 1
Boston 1
Brooklyn 1
Dallas 1
Dalsjoefors 1
Fiesole 1
Ho Chi Minh City 1
Manchester 1
Montreal 1
Nova Mamoré 1
Ottawa 1
Phoenix 1
Pittsburgh 1
Pune 1
Toronto 1
Vilnius 1
Zanica 1
Totale 164
Nome #
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project 185
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study 178
OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study 171
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study 165
Phylogenetic Analysis of Multi-Drug Resistant Klebsiella pneumoniae Strains From Duodenoscope Biofilm: Microbiological Surveillance and Reprocessing Improvements for Infection Prevention 162
Advances on Human Immunodeficiency Virus Type 2 Infection 95
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients 87
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study 78
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study 71
Totale 1.192
Categoria #
all - tutte 3.859
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.859


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 0 0 0 0 0 0 0 0 0 0 0 20
2022/202313 0 0 0 1 4 0 2 1 3 0 2 0
2023/202432 0 3 1 10 2 7 0 6 2 0 0 1
2024/20251.084 8 7 10 3 1 12 8 4 20 47 486 478
2025/202643 29 14 0 0 0 0 0 0 0 0 0 0
Totale 1.192